Adva Biotechnology Ltd. and Autolomous Ltd. have announced a strategic collaboration to co-lead the Digital Pioneer Program, an early adopter initiative aimed at digitising, decentralising, and scaling autologous cell therapy manufacturing.

The program combines Adva’s automated, closed-system manufacturing platform with Autolomous’ advanced digital orchestration and manufacturing management technologies. The integrated solution is designed to ensure right-first-time production, full data traceability, and compliance, helping reduce the overall time-to-patient for life-saving therapies.

“Through the Digital Pioneer Program, we are inviting cell therapy developers to experience the real-world benefits of a unified, intelligent manufacturing model,” said Dr Ohad Karnieli, founder and CEO of Adva Biotechnology. “This collaboration is about enabling a new standard—one where automation, digital traceability, and scalability are built into the therapeutic lifecycle from day one.”

“Our mission is simple: to bring life-saving therapies to all patients around the world, safer, faster, and affordable. By providing a digital-first infrastructure to the industry, we are removing the barriers between innovation and the patient,” said Alexander Seyf, co-founder and CEO of Autolomous.

“This program is a call to action, offering a foundation that will help us build the future of personalised medicine — one defined by trust, equity, and most importantly, acting for hope.”

The Digital Pioneer Program is now open for inquiries from cell therapy developers interested in adopting next-generation manufacturing technologies.